Commercial packages. The Supplier undertakes that the commercial package shall have a valid item number in Farmalogg.
Commercial packages. The Supplier undertakes to deliver the pharmaceutical drug which at the time of delivery have a shelf life equal to, or longer, than 12 months. The shelf life requirement in the first paragraph does not apply if the pharmaceutical drug for regulatory reasons have a shorter shelf life. If the Supplier receives an order for the pharmaceutical drug and the Supplier only has the pharmaceutical drug with a remaining shelf life of less than 12 months, the Supplier undertakes to notify the Wholesaler(s) and await acceptance of the shelf life before confirming the order and delivery is carried out.
Commercial packages. The Supplier undertakes to accept returns and credit the value of returned pharmaceutical drug from the Wholesaler(s) in the following cases: • If the pharmaceutical drug is deregistered by the Norwegian Medicines Agency. • If the pharmaceutical drug is withdrawn from sale by order of the Norwegian Medicines Agency. • If the pharmaceutical drug has quality defects. Exceptions from this apply if damages or quality defects occur in the distribution chain from the Wholesaler(s). • If the pharmaceutical drug is outdated, presumed that the Wholesaler(s) follows the ‘first expired, first out”-principle. The same applies for return of the pharmaceutical drug that has been delivered with a remaining shelf life of less than 12 months, independent of the cause for shorter shelf life. • At the end of the duration of the Framework Agreement, the Wholesaler(s) have the right to adjust stock by returning the pharmaceutical drug that is unsold, given that the Supplier no longer has an agreement to deliver the pharmaceutical drug or that the Supplier has entered into a new agreement where significantly smaller volume of the pharmaceutical drug is expected. Any return is to be made within four (4) months after the end of the duration of the Framework Agreement. Handling and transport costs with regards to returns shall be covered by the Supplier. The Wholesaler(s) with license issued by the Norwegian Medicines Agency are obliged by regulations (forskrift om grossistvirksomhet med legemidler av 21. desember 1993 nr. 1219 § 9) to adhere to the EU Commission´s guidelines on good distribution practice (GDP). Any return of the pharmaceutical drug from the Wholesaler(s) to the Supplier presumes compliance to GDP 6.3 throughout the supply chain. As an alternative to returning the pharmaceutical drug to the Supplier, the Wholesaler(s) may carry out destruction of the pharmaceutical drug. The Wholesaler(s) must obtain written consent from the Supplier prior to destruction. Furthermore, the following conditions must be met: • The pharmaceutical drug that are to be destructed shall be stated in the monthly return message, and the Supplier credit the Wholesaler(s) for the value (the actual purchase price) at the current price of the time of return. • To cover costs for return and destruction, the Wholesaler(s) invoices the Supplier a minimum fee of NOK 3500 or 1 % of invoiced actual purchase price, in accordance with the Framework Agreement Chapter 2, for the returned / destructed pha...
Commercial packages. If the pharmaceutical drug fails to fulfil the requirements set out in the Framework Agreement, this shall be considered a breach. If a Party to the Framework Agreement fails to fulfil its obligations under the Framework Agreement, this shall be considered a breach. This does not apply if the situation is due to the other Party´s circumstances or Force Majeure. In the event the Wholesaler(s) or the Contract Manager addresses the Supplier regarding a breach, the Supplier undertakes to follow up the inquiry no later than the following business day.
Commercial packages. The Customer´s price for the pharmaceutical drug is 10 % of the maximum price set by the Norwegian Medicines Agency, limited upwards to NOK 100 000 (both amounts in ‘LIS GIP’; the Wholesaler(s) purchasing price as per the Customer´s agreement with the Supplier) per year per patient.
Commercial packages. The pharmaceutical drug shall be delivered to the Wholesaler(s) in accordance with Incoterms DDP (2020). Delivery to the Wholesaler(s) (commercial packages) shall otherwise take place in accordance with the agreements between the Supplier and the Wholesaler(s), and at a minimum in accordance with the terms of the Framework Agreement.
Commercial packages. The pharmaceutical drug shall be delivered to the Wholesaler(s), at current time Alliance Healthcare Norge AS, Langhus.
Commercial packages. In the event of delayed or non-delivery, the Suppliers hall immediately notify the Hospital Pharmacy Enterprise, the Norwegian Medicines Agency, and the Contract Manager. This also applies to incidents that could potentially lead to future deviations in delivery. The information shall contain the reason for the deviation, what measures are taken, expected delivery time and quantity per item number. The contact information is set out in Appendix 2. In the event of a delay, following an agreed transition to commercial packages, the Contract Manager may demand daily fines and compensation from the Supplier, cf. Section 10. If a delay results in the product not being able to be used within the agreed period of use, the Customer / Wholesaler(s) may cancel the order (call off). This also applies to a notified delay in the first paragraph.
Commercial packages. The Supplier undertakes to pay a fee to Nomvec AS (The Norwegian Medicines Verification Company) for operation of the medicines verification system in the duration of the Framework Agreement. The Supplier shall provide documentation to the Contract Manager upon request.
